Relugolix Synthesis With Sequential Purification and Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for the synthesis of relugolix, a GnRH receptor antagonist, are inefficient and lack a method for producing high-purity crystalline relugolix, which is crucial for pharmaceutical applications.
Innovation Solution
A novel process involving sequential reactions including reduction, coupling, hydrolysis, and cyclization steps, followed by crystallization from a dimethylacetamide-alcohol mixture, to obtain relugolix with specific XRPD peaks, ensuring high purity and crystallinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing synthesis processes are used, then relugolix can be produced, but the purity is insufficient and impurities remain high
Solution Approach 1:
The synthesis process is divided into distinct sequential steps (reduction, coupling, hydrolysis, cyclization) with isolated purification stages. Each step is optimized independently to minimize impurity carryover, and intermediate compounds are purified before proceeding to the next transformation, thereby achieving high overall purity
Solution Approach 2:
Crystallization is introduced as an intermediary purification step between synthesis and final product formation. The crystallization process selectively precipitates pure relugolix from the reaction mixture, separating it from impurities and enabling high-purity product isolation
2Manufacturing precision
If a crystallization method is introduced, then high-purity crystalline relugolix can be obtained, but the process complexity increases
Solution Approach 1:
The crystallization step is integrated into the existing synthesis workflow as a continuous operation rather than a separate batch process. The reaction mixture proceeds directly from the cyclization step into crystallization conditions, maintaining process flow and minimizing additional equipment requirements
Solution Approach 2:
Crystallization is achieved by modifying physical parameters (temperature, solvent composition, pH) of the existing reaction mixture rather than introducing new chemical reagents or complex separation equipment. This allows high-purity crystalline product formation using simple parameter adjustments
3Productivity
If sequential reactions are performed without isolating intermediates, then productivity increases, but controlling reaction selectivity becomes difficult
Solution Approach 1:
Each reaction step is designed with preliminary optimization of conditions (catalyst selection, temperature, stoichiometry) to ensure high selectivity before proceeding to the next step. The reduction, coupling, hydrolysis, and cyclization steps are each pre-configured to minimize side reactions, allowing continuous processing without intermediate isolation
Solution Approach 2:
The process incorporates monitoring and control mechanisms at each transformation step to detect and correct deviations from optimal selectivity. Reaction progress and product purity are monitored, and parameters are adjusted in real-time to maintain high selectivity throughout the sequential process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process yields high-purity crystalline relugolix with reduced impurities, enhancing its suitability for pharmaceutical use, particularly in treating advanced prostate cancer and managing heavy menstrual bleeding.
Implementation Method 1
reduction of a compound of formula XIX to obtain a compound of formula XVIII
Implementation Method 2
hydrolysing the compound XVII to obtain a compound of formula XVI
Implementation Method 3
crystallization from a dimethylacetamide-alcohol mixture, to obtain relugolix with specific XRPD peaks
Implementation Method 4
X-ray powder diffraction (XRPD) spectrum having peak reflections at about 7.3, 8.9, 9.9, 12.0, 16.6, 17.3, 22.2, 22.7, and 27.4±0.2 degrees 2 theta
Data Source
AI summary
The present invention is related to a process for the preparation of relugolix, a compound of formula I, also known as N-[4-[1-[(2,6-difluoro phenyl) methyl]-5-[(dimethyl amino]-methyl]-3-(6-methoxy-3-pyridazinyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidin-6-yl]phenyl]-N′-methoxyurea, or a pharmaceutically acceptable salt thereof. The present invention is also related to a process for the preparation of crystalline relugolix.